Investment Activity - Bain Capital agreed to invest in PCI Pharma Services [1] Industry Focus - PCI Pharma Services is a drug services provider that helps assemble and package medicines [1]

Exclusive: Bain Capital and Kohlberg are leading an investment valuing biotech firm PCI Pharma at $10 billion including debt https://t.co/3GERxnWOIJ ...

Canada Goose’s controlling shareholder Bain Capital is considering a sale of its stake in the luxury parka-maker https://t.co/GtVG4YqVTP ...

Warner Music and Bain Capital are joining together to invest as much as $1.2 billion in iconic music catalogs. https://t.co/B0CMZR0deh ...

Core Insights - Warner Music Group (WMG) and Bain Capital are launching a joint venture to acquire up to $1.2 billion in music catalogs, encompassing both recorded music and music publishing [1][2] - The partnership aims to provide artists and songwriters with opportunities to preserve and expand their catalogs, ensuring their legacies are well managed [2][4] - The deal is timely for the music industry, as changing fan behavior driven by streaming and technology is introducing classic music to new audiences [3] Company Overview - Warner Music Group operates in over 70 countries and includes renowned labels and a music publishing arm with over one million copyrights across various genres [6] - Bain Capital, founded in 1984, is a leading private investment firm with approximately $185 billion in assets under management and a commitment to creating lasting impact [7] Strategic Implications - The joint venture combines WMG's global infrastructure and relationships with Bain Capital's financial resources, positioning it as a preferred partner for iconic musical talent [2][4] - The collaboration emphasizes the importance of catalog stewardship, aiming to enhance the value of artists' work while delivering new collaborations to fans [4] Financial Arrangements - Goldman Sachs and Fifth Third Bank will serve as joint lead arrangers for the joint venture [4]

Core Viewpoint - Envestnet plans to sell its subsidiary Yodlee to private equity firm STG, allowing Envestnet to focus on its core wealth management offerings [1][4]. Group 1: Transaction Details - The sale of Yodlee is expected to close in the third quarter, pending customary closing conditions [2]. - STG specializes in investing in innovative software, data, and analytics firms, and Yodlee will be integrated into STG's global technology portfolio [2]. Group 2: Strategic Implications - STG's managing director, Marc Bala, stated that the partnership will enhance Yodlee's investment in product innovation, customer success, and long-term growth [3]. - Yodlee aims to focus on technological innovation and improved solutions for the financial sector with STG's support [3]. Group 3: Envestnet's Focus - Envestnet's CEO, Chris Todd, indicated that the transaction will enable the company to concentrate on its core offerings, including its wealth management platform [4]. - Envestnet retains access to Yodlee's data aggregation technology, which is essential for financial advisors [5]. Group 4: Company Background - Envestnet became a private company in November after being acquired by Bain Capital affiliates in a deal valued at approximately $4.5 billion [5]. - The company reported $6.5 trillion in platform assets, over 20 million accounts, and services more than 111,000 financial advisors [6]. - Envestnet is enhancing its wealth management solutions by investing in tax intelligence, trading flexibility, client engagement, and advisor productivity [6]. Group 5: Historical Context - Envestnet acquired Yodlee in 2015 for a cash and stock transaction valued at about $660 million [7].

Core Insights - Federal Life Insurance Company has acquired Texas Service Life Insurance Company, enhancing its position in the preneed insurance market and demonstrating a commitment to growth and innovative solutions for families [1][3] - The acquisition is seen as a strategic move to address an underserved market, with Federal Life aiming to redefine how families prepare for the future through exceptional service and innovative preplanning opportunities [3][4] - Federal Life holds an A- (Excellent) rating from AM Best and is backed by Bain Capital, indicating a strong financial foundation for future growth in the preneed insurance sector [2] Company Overview - Federal Life Insurance Company focuses on innovative insurance solutions that protect individuals and families throughout their lives, emphasizing financial strength and stability [5] - Texas Service Life Insurance Company has been operational since 1985, known for its reliability and strong financial foundation in the insurance industry [6] Leadership and Strategy - Knut Olson, CEO of Federal Life, emphasizes the importance of preneed insurance as a vital product for families and the company's readiness to drive industry change [3] - George Wise has been appointed as President of Texas Service Life, tasked with leading a national expansion strategy that prioritizes accessibility and financial security for families [3][4]

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is June 3, 2025, which requires a motion to the Court [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including over $438 million recovered for investors in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023 [5]. - The secondary offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement [5]. - Following the offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly in securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the true details were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].